Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.

ABSTRACT: Emerging antimalarial drug resistance may undermine current efforts to control and eliminate Plasmodium vivax, the most geographically widespread yet neglected human malaria parasite. Endemic countries are expected to assess regularly the therapeutic efficacy of antimalarial drugs in use in order to adjust their malaria treatment policies, but proper funding and trained human resources are often lacking to execute relatively complex and expensive clinical studies, ideally complemented by ex vivo assays of drug resistance. Here we review the challenges for assessing in vivo P. vivax responses to commonly used antimalarials, especially chloroquine and primaquine, in the presence of confounding factors such as variable drug absorption, metabolism and interaction, and the risk of new infection

SUBMITTER: Ferreira MU 

PROVIDER: S-EPMC7770540 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature